Edward Cline, DPM, FACFAS
: American Board of Podiatric Surgery
: Broadlawns Medical Center, Des Moines, IA
: College of Podiatric Medicine & Surgery, University of Osteopathic Medicine and Health Science, Des Monies, IA
Dr. Cline offers comprehensive care of foot and foot related disorders such as:
- Diabetic foot care
- Diabetic Shoe Gear Program
- Non-surgical treatment of athletic injuries
- Custom-molded Orthotic shoe gear
- Foot surgery
- Work-related injuries
- Minor in-office surgical procedures
- Extracorporeal shock wave therapy for plantar fascitis
In addition, the following medical and surgical treatments are available for:
- Foot pain
- Arch Disorders
- Heel Spurs
- Ingrown Toenails
- Reconstructive Foot Surgery
- Trauma and Athletic Injuries
- Surgical and Non-surgical Treatment for Neuromas
- Tendon and Joint Pain
- Sports injuries
- Diabetic Care
- Infections and ulcerations
- Burning pain
- Soft tissue masses and tumors
At Hannibal Regional Medical Group we offer innovative world class solutions in health care. One of those solutions is skin grafting using Dermagraft®, the leader in skin graft technology.
Check out the Dermagraft Patient Guide - Click Here!
Dermagraft® is a cryopreserved human fibroblast-derived dermal substitute; it is composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold.
Dermagraft is manufactured from human fibroblast cells derived from newborn foreskin tissue. During the manufacturing process, the human fibroblasts are seeded onto a bioabsorbable polyglactin mesh scaffold. The fibroblasts proliferate to fill the interstices of this scaffold and secrete human dermal collagen, matrix proteins, growth factors, and cytokines to create a three-dimensional human dermal substitute containing metabolically active, living cells.
Dermagraft does not contain macrophages, lymphocytes, blood vessels, or hair follicles.
Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than 6 weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. Dermagraft should be used in conjunction with standard wound care regimens and in patients who have adequate blood supply to the involved foot. Dermagraft is supplied frozen in a clear bag containing one piece of approximately 2” x 3” for a single-use application.
• Description: Human fibroblast-derived dermal substitute
• Composition: Composed of human fibroblasts, extracellular matrix, and bioabsorbable scaffold; does not contain macrophages, lymphocytes, blood vessels, or hair follicles
• Cultured: In vitro
• Mode of Action: Re-epithelialization—assists in the restoration of the dermal bed, allowing wounds to heal (when implanted into adequately prepared diabetic foot ulcers)
• Primary Indication: For use in the treatment of full-thickness diabetic foot ulcers
• Product Number 11045
Dermagraft® is manufactured by Advanced BioHealing, of La Jolla, CA.
Dermagraft is a registered trademark of Advanced BioHealing, Inc.
Caution: Federal [US] law restricts this device to sale by or on the order of a physician or properly licensed practitioner.